Evidence map›Paper›PMID 39199130›Full record

ArticleAntioxidants (Basel, Switzerland)2024

Exploring the Therapeutic Potential of Green-Synthesized Gold Nanoparticles and

Nayana Freire de Almeida Fontes, Mário Fernandes, Noelia González-Ballesteros, Maria Carmen Rodríguez-Argüelles, Andreia Castro Gomes, Antoniella Souza Gomes Duarte

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nayana Freire de Almeida FontesDepartamento de Morfologia, Faculdade de Medicina, Centro de Ciências da Saúde, Universidade Federal do Ceará, Fortaleza 60440-900, Brazil.
Mário FernandesCentre of Molecular and Environmental Biology (CBMA)/Aquatic Research Network (ARNET) Associate Laboratory, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
Noelia González-BallesterosDepartamento de Química Inorgánica, Universidade de Vigo, 36310 Vigo, Spain.ORCID 0000-0001-5514-1984
Maria Carmen Rodríguez-ArgüellesDepartamento de Química Inorgánica, Universidade de Vigo, 36310 Vigo, Spain.
Andreia Castro GomesCentre of Molecular and Environmental Biology (CBMA)/Aquatic Research Network (ARNET) Associate Laboratory, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal.ORCID 0000-0002-0567-064X
Antoniella Souza Gomes DuarteDepartamento de Morfologia, Faculdade de Medicina, Centro de Ciências da Saúde, Universidade Federal do Ceará, Fortaleza 60440-900, Brazil.

Funding

European Union NextGenerationEU/PRTR Margarita SalasFundação para a Ciência e Tecnologia https://doi.org/10.54499/UIDB/04050/2020Fundação para a Ciência e Tecnologia SFRH/BD/147819/2019Spanish Ministry of Universities 33.50.460A.752
6 · The paper itself

Abstract

Addressing disease remission and treatment adherence in inflammatory bowel diseases (IBDs), such as Crohn's disease, poses significant challenges due to underlying oxidative and inflammatory processes. Nanotechnology emerges as a promising avenue for enhancing therapeutic outcomes in IBD by optimizing drug bioactivity, reducing toxicity, and extending circulation time. Gold nanoparticles, known for their resistance to gastrointestinal pH and possessing antioxidant and anti-inflammatory properties, offer particular promise. They can be produced by green synthesis with seaweed

Indexed as

anti-inflammatoryantioxidantEricaria selaginoidesgold nanoparticlesgreen synthesisinflammatory bowel diseasemacroalgae

Identifiers

PMID39199130
PMCPMC11351725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.